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Objectives This study sought to quantify the learning curve for the safety and effectiveness of a
newly introduced vascular closure device through evaluation of the NCDR (National Cardiovascular
Data Registry) CathPCI clinical outcomes registry.
Background The impact of learning on the clinical outcomes complicates the assessment of the
safety and efﬁcacy during the early experience with newly introduced medical devices.
Methods We performed a retrospective analysis of the relationship between cumulative institutional
experience and clinical device success, deﬁned as device deployment success and freedom from any
vascular complications, for the StarClose vascular closure device (Abbott Vascular, Redwood City,
California). Generalized estimating equation modeling was used to develop risk-adjusted clinical suc-
cess predictions that were analyzed to quantify learning curve rates.
Results A total of 107,710 procedures used at least 1 StarClose deployment, between January 1, 2006,
and December 31, 2007, with overall clinical success increasing from 93% to 97% during the study pe-
riod. The learning curve was triphasic, with an initial rapid learning phase, followed by a period of declin-
ing rates of success, followed ﬁnally by a recovery to a steady-state rate of improved device success. The
rates of learning were inﬂuenced positively by diagnostic (vs. percutaneous coronary intervention) proce-
dure use and teaching status and were affected inversely by annual institutional volume.
Conclusions An institutional-level learning curve for the initial national experience of StarClose was
triphasic, likely indicating changes in patient selection and expansion of number of operators during
the initial phases of device adoption. The rate of learning was inﬂuenced by several institutional fac-
tors, including overall procedural volume, utilization for percutaneous coronary intervention proce-
dures, and teaching status. (J Am Coll Cardiol Intv 2012;5:82–9) © 2012 by the American College of
Cardiology Foundation
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83A learning curve can be defined as a proportional improve-
ment in performance, such as the clinical outcomes of a
medical procedure, with each doubling of cumulative expe-
rience (1). Whereas learning curve effects have been quan-
tified in numerous industries outside of health care, within
medicine, characterizing learning curve effects has been
challenging. Analyses of surgical outcomes (2–4), interven-
tional cardiology procedures (5,6–8), and improvements in
single center outcomes (9–11) have all demonstrated the
presence of learning effects for medical procedures. How-
ever, there has been limited investigation of the learning
effect with regard to specific medical devices, often due to
insufficient sample size to quantify the effect. In addition,
learning effects must be distinguished from traditional
steady-state “volume-outcome” relationships in which
higher volume providers or centers have typically been
shown to have improved outcomes relative to lower volume
providers (12–14). Separating the impact, over time, of
secular improvements in care, changes in clinical practice,
including case selection, and the impact of institutional
operator learning can be quite challenging, but these are
critical to understanding the safety and effectiveness of new
devices and procedures.
In this study, we sought to quantify the learning curve for
the safety and effectiveness of a newly introduced vascular
closure device (VCD) through the evaluation of the NCDR
(National Cardiovascular Data Registry) CathPCI data
registry. Within the broad population of centers and phy-
sicians reporting to this registry, VCD are used in more
than 45% of cardiac catheterization procedures to achieve
hemostasis at the femoral arteriotomy site (15). Given the
relatively high usage rate, VCD represent an excellent
opportunity for studying learning effects because these
devices have been adopted across a broad spectrum of
practice environments, clinical outcomes can be easily iden-
tified, and standardized clinical data definitions are widely
accepted. Understanding the learning curve associated with
VCD implants is important, because vascular complications
following catheterization procedures are powerful indepen-
dent predictors of morbidity and long-term mortality (15).
In addition, VCD deployment failure has been shown to
increase significantly the risk of vascular complications (16).
Therefore, we performed a retrospective analysis of the
relationship between cumulative institutional experience
and clinical device success, defined as device deployment
success and absence of vascular complications, for the
StarClose VCD (Abbott Vascular, Redwood City, Califor-
nia), approved for clinical use in the United States on
December 21, 2006. We hypothesized that a learning curve
could be quantified from cumulative outcomes data and that
the learning rates would be affected by a variety of institution
factors, including procedural volume, prior experience with
VCD, teaching status, and type of procedures performed.Methods
A retrospective analysis of the NCDR CathPCI registry
data were performed to assess changes in successful deploy-
ment rates and clinical outcomes following the deployment
of StarClose VCD between January 2005 and December
2007. A total of 1,650,953 patient visits, from 797 partici-
pating institutions, which included diagnostic catheteriza-
tion procedures and/or percutaneous coronary intervention
(PCI), were included. Patients were excluded who under-
went nonfemoral vascular access procedures, who had pro-
cedures at centers providing incomplete CathPCI datasets,
or who had an intra-aortic balloon pump inserted at the
time of cardiac catheterization. Clinical success was defined
as a procedure with successful device deployment, as re-
ported by the implanting operator, and no reported vascular
complication during the hospitalization. Vascular complica-
tions were defined per standard American College of
Cardiology–NCDR definitions (17) and included access-
site bleeding, retroperitoneal hemorrhage, access-site occlu-
sion, peripheral embolization, arterial dissection, pseudoan-
eurysm, and arteriovenous fistula. The learning curve was
estimated using the performing
center (hospital) as the funda-
mental unit of analysis, explor-
ing the impact of accumulating
volume of StarClose VCD de-
ployments on observed center-
specific clinical success rates.
In addition, to further charac-
terize the factors influencing the
learning curve, predefined sub-
groups were analyzed based on type of procedure (diagnostic
vs. interventional), annual institutional procedural volume,
and teaching status of the institution (teaching vs. non-
teaching institution). Of note, physician-specific identifier
information was inconsistently documented in the NCDR
registry, such that reasonable estimates of individual expe-
rience with the VCD studied were not available. From prior
analyses using the CathPCI dataset, it was known that there
is relatively little missing data, due to software requirements for
complete case-level data submissions. For this analysis, missing
data for any covariate was imputed to have a value of “none” or
“negative” for categorical variables and was estimated as sex-
specific mean values for continuous variables.
A logistic regression model was used to adjust for
variables that might influence clinical success following
StarClose deployment. The model was based on previously
published clinical factors that predict rates of vascular
complication following VCD use (15,18,19–21) and in-
cluded age, sex, race, prior congestive heart failure, prior
myocardial infarction, body mass index, peripheral vascular
disease, chronic lung disease, cerebrovascular disease, renal
Abbreviations
and Acronyms
GEE  generalized
estimating equation
PCI  percutaneous
coronary intervention
VCD  vascular closure
device(s)failure, diabetes, hypertension, prior coronary artery bypass
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84grafting, cardiogenic shock, and presentation with acute
coronary syndrome. Generalized estimating equation
(GEE) modeling, with clustering by center, was used to
develop risk-adjusted clinical success predictions that were
analyzed by institutional volume to quantify learning curve
rates. A spline transformation was performed using the
GEE results to quantify the effect of increasing institutional
experience on clinical success during each phase of an
experience curve that appeared to be noncontinuous. Insti-
tutions were stratified into quartiles based on volumes of
StarClose VCD deployment, and 4 separate GEE models
were fitted for each strata of institutional volume. The
chi-square test was used for comparisons of categorical data,
and the 2-tailed Student t test was used to compare
ontinuous variables. A p value 0.05 was considered
statistically significant for all comparisons. All statistical
analyses were performed using SAS software (version 9.2,
SAS Institute Inc., Cary, North Carolina).
Results
Among the original study cohort, 107,710 procedures at
468 institutions between January 2005 and December 2007
included the deployment of at least 1 StarClose VCD and
were included in this analysis. Baseline characteristics of the
study population are summarized in Table 1. The study
population included 40% women, 28% diabetics, and 8.2%
patients with a history of peripheral arterial disease. In
addition, of the 107,710 procedures analyzed, 31,012
(29.6%) were PCI procedures. Hospitals included in the
analysis were representative of the CathPCI registry and
included generally larger volume centers, with 57% having
an annual PCI procedural volume of more than 500 cases
and 47% having post-graduate teaching programs (Table 2).
As predicted, there was little missing data in the analyzed
dataset, with no covariates having more than 7.5% missing
data. Only 1.96% of patients undergoing left heart cathe-
terization and/or coronary intervention were excluded from
the analysis due to use of nonfemoral access sites (brachial or
radial) or due to the use of intra-aortic balloon.
Access site bleeding complications were documented in
461 patients (0.43%), whereas retroperitoneal bleeding was
found to occur in 162 (0.15%) patients. Any vascular
complication was documented in 1.33% of patients (Table 3).
The overall StarClose device deployment failure rate was
found to be approximately 5% and was the major determi-
nant of clinical success.
The overall clinical success rate increased from 93% to
97% with increasing institutional experience over a 2-year
period (Fig. 1). This learning effect translated into a 30%
reduction in clinical failure rate with each doubling of
cumulative institutional experience. Institutional learning
curve effects were observed in multiple subgroups and were
positively correlated with increasing annual catheterization ilaboratory volume of the institution. Higher rates of clinical
success were observed in the diagnostic, compared with the
PCI group, with difference in success declining from 5.6%
during the initial phase of institutional experience to 3%
with growing institutional experience (Fig. 2). The GEE
models fitted for each of the institutional volume strata
demonstrated adequate discrimination for the purpose of
exploring the main effect (device-specific experience) on the
clinical success rate adjusted by other possible confounders,
with C-indexes ranging from 0.57 to 0.61.
The rate of learning (i.e., slope of the learning curve) was
influenced by diagnostic (vs. interventional) procedures
(more rapid improvement for interventional procedures),
teaching status of the institution (more rapid with non-
teaching status), and annual institutional volume (more
rapid with smaller institutional volumes). Figure 3 illustrates
he clinical success rate of StarClose deployment with
ncreasing average StarClose experience per operator, strat-
Table 1. Baseline Characteristics of Study Population
Number of
Procedures
Proportion
(%)
StarClose procedures, N 107,710 100.0
Age, mean  SD, yrs 62.5 12.5
Female 43,205 40.1
Body mass index, mean  SD, kg/m2 30.1 6.6
Medical history
Prior MI, 7 days 20,836 19.3
Diabetes mellitus 29,770 27.6
Renal insufﬁciency 4,855 4.5
Renal dialysis 1,454 1.3
Peripheral vascular disease 8,878 8.2
Hypertension 73,761 68.5
Smoking 56,434 52.4
Dyslipidemia 69,755 64.8
Prior PCI 28,263 26.2
CABG surgery 15,530 14.4
Clinical presentation on admission
Unstable angina 32,179 29.9
Non-STEMI 9,159 8.5
STEMI 4,060 3.8
Presence of cardiogenic shock 585 0.5
Medications on admission
Aspirin 79,648 73.9
Warfarin 3,897 3.6
Glycoprotein IIb/IIIa inhibitor 13,194 12.2
Low molecular weight heparin 14,284 13.3
Heparin (unfractionated) 26,650 24.7
Bivalirudin (or other direct thrombin inhibitor) 14,079 13.1
Clopidogrel 41,441 38.5
Thrombolytics 804 0.7
CABG coronary artery bypass graft; MImyocardial infarction; PCI percutaneous coronary
intervention; STEMI ST-segment elevation myocardial infarction.fied by annual institutional volume.
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85As illustrated in Figure 3, annual hospital volume of StarClose
device deployments, normalized by the average experience per
operator performing procedures at the institution, appears to
influence significantly the rates of learning. Lower volume insti-
tutions required few StarClose deployments per operator to
achieve high rates of clinical success as compared with larger
volume institutions. At lower volume centers, 98% clinical success
rates were predicted after the first 75 StarClose deployments per
operator. At the highest volume centers (2,400 total procedures
nnually), an average StarClose deployment volume of 130 cases
er operator was required to achieve a clinical success rate of 98%.
In addition, a triphasic learning pattern emerged in institutions
ith larger annual volumes, as shown for the largest volume
enters with 2,400 device deployments in Figure 4. This
riphasic distribution is characterized by a rapid initial learning
hase (phase I), followed by a period of declining procedural
uccess (phase II), followed by recovery to a steady state of
mprovement with increasing experience (phase III). Whereas the
bsolute differences in the rates of procedural success were small
94% in phase I to 92% in phase II), these changes represent a
7% increase in the rate of procedural failure (p  0.001).
hanges in the characteristics of patients treated in each of the
hases of the learning curve were explored in an effort to
nderstand the potential impact of patient selection on the
bserved differences in outcomes and rates of learning between
hases I, II, and III of the learning curve (Table 4). The
Table 2. Hospital Characteristics
Number of
Hospitals
Proportion
(%)
Analysis sample 468 100
Rural 88 18.8
Suburban 141 30.1
Urban 239 51.1
Proﬁt type
Government 7 1.5
Private/community 418 89.3
University 43 9.2
Fellowship, internship, or residency program 221 47.2
Hospital Region
West 97 20.7
Northeast 55 11.8
Midwest 145 31.0
South 169 36.1
Average annual PCI volume, mean  SD 714 559
Average annual PCI volume
500 191 40.8
500 and 1,000 178 38.0
1,000 and 1,500 42 9.0
1,500 and 2,000 31 6.6
2,000 16 3.4
PCI percutaneous coronary intervention.roportion of patients with a variety of high-risk clinical condi-ions, including: diabetes, dialysis, urgent procedure status,
CI (compared with diagnostic procedures), and use of glyco-
rotein IIb/IIIa antagonists declined significantly from phase
I to phase III in the large institutions studied (1,600
rocedures per year). These changes in the composition of
atients selected to receive the StarClose VCD likely contrib-
ted to the overall improvement to observed outcomes in the
ater phases of experience with the device. There was also no
ignificant change in the use of bivalirudin between phases II
nd III, indicating that the use of direct thrombin inhibitors
as unlikely to be related to the observed differences in rates of
linical success with the StarClose device.
iscussion
This retrospective exploration of more than 100,000 device
deployments in over 460 U.S. healthcare institutions repre-
sents the largest analysis of medical implant device learning
Table 3. Catheterization Procedure Details
Number of
Procedures
Proportion
(%)
Total number of StarClose procedures 107,710 100
Right heart catheterization 9,048 8.4
Left heart catheterization 101,213 94.0
Percutaneous coronary intervention 31,912 29.6
Intra-aortic balloon pump 250 0.2
Mean ejection fraction, mean  SD 55 12
Number of diseased vessels
0 45,772 42.5
1 24,968 23.2
2 18,019 16.7
3 17,980 16.7
Multivessel disease 35,999 33.4
Details of hospital stay
Inpatient 55,041 51.1
Outpatient 46,445 43.1
Post-procedure length of stay, days
1 and 2 50,359 46.8
2 and 4 40,950 38.0
4 16,401 15.2
Adverse outcomes
Bleeding at percutaneous entry site 461 0.4
Retroperitoneal bleeding 162 0.2
Gastrointestinal bleeding 137 0.13
Genital-urinary bleeding 47 0.0
Other/unknown cause 480 0.4
Access site occlusion 24 0.0
Peripheral embolization 17 0.0
Dissection 64 0.1
Pseudoaneurysm 85 0.1
AV ﬁstula 14 0.0
Any vascular complication 198 0.2AV arteriovenous.
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86curve effects. Whereas successful deployment of the
StarClose VCD was associated with previously reported
clinical factors, including patient sex, body mass index,
anticoagulation status, prior history of peripheral vascular
disease, and deployment following a PCI procedure (vs.
diagnostic-only procedure), our data suggest a strong asso-
ciation between clinical success and accumulating experi-
ence with the specific VCD. This learning effect was
associated with increasing institutional clinical success,
which improved from 93% to 97% over the study period.
On average, the improvement in clinical success rate repre-
sented an approximate 1.5% increase in clinical success with
each doubling of experience with the VCD. The rate of
learning (slope of the learning curve) was influenced by
diagnostic versus interventional procedure status, teaching
status of the institution, and average institutional volume.
Figure 1. Overall Learning Experience Across 107,710 Deployments of the
The graphic displays the estimated clinical success rate, deﬁned as the frequen
complication versus cumulative institutional experience with the StarClose vas
the estimated success rate. NCDR  National Cardiovascular Data Registry.
Figure 2. Learning Experience for Diagnostic Versus Coronary Intervention
The graphic displays the clinical success rate, deﬁned as the frequency of successf
stratiﬁed by diagnostic-only procedures (blue) and coronary interventional pro
Dashed lines indicated the 95% conﬁdence interval of the estimated success rate. PThe significant differences in the learning curves seen in
Figure 3, stratified by hospital volume, represents a paradox in
that the trend does not follow the typical relationship between
higher volume centers and lower adverse event rates (the
“volume-outcome” relationship). In this analysis, it is the
smaller centers that appear to achieve high steady-state proce-
dural success rates more quickly, perhaps indicating a more
rapid diffusion of learning among a smaller number of opera-
tors (a “shared learning” effect). Similarly, the difference in rates
of learning between teaching and nonteaching centers may
have been influenced by the presence of trainees in the larger
teaching institutions, which could not be directly accounted for
in this analysis. Because it is common practice in the United
States to have the VCD deployment performed by a senior
trainee (fellow), the presence of trainees and larger numbers of
procedural assistants at teaching hospitals may well have
lose VCD in 468 Institutions Reporting to NCDR CathPCI
successful device deployment without subsequent occurrence of access site
losure device (VCD). Dashed lines indicated the 95% conﬁdence interval of
cedures
ice deployment without subsequent occurrence of access site complication,
es (red) versus cumulative institutional experience with the StarClose VCD.StarC
cy of
cular cal Pro
ul dev
cedurCI  percutaneous coronary intervention; VCD  vascular closure device.
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87contributed to “slower” observed learning as compared to
smaller, nonteaching centers. Whereas the rates of improve-
ment in clinical success were higher in interventional
procedures, compared with diagnostic procedures, this
finding is due to the very high rates of initial clinical
success for diagnostic procedures using the StarClose
VCD such that gains attributable to learning were more
modest in diagnostic procedures.
For larger institutions, the learning curve for StarClose
VCD appeared to be triphasic, with a period of declining
success interposed between an initial and a final period of
typical learning. This observed variation in learning curve
may be due to changes in patient selection and expansion of
Figure 3. Learning Experience in Use of StarClose VCD Stratified by Annua
The graphic displays the clinical success rate, deﬁned as the frequency of successf
stratiﬁed by catheterization laboratory procedural volume versus cumulative avera
Figure 4. Triphasic Learning Curves Illustrated in the Largest Hospital Qua
The graphic displays the clinical success rate, deﬁned as the frequency of succ
tion, versus cumulative average operator experience with the StarClose vascul
learning (phase I), between 0 to 22 average operator implants, declining clinic
steady-state learning (phase III), beyond approximately 50 StarClose VCD implants pnumber of operators during the initial adoption of the VCD
at the institution, though only small differences in patient
risks and characteristics were noted in this study.
Whereas this analysis demonstrates improvement in clin-
ical success with StarClose, with accumulating experience,
this finding does not appear to be driven by secular
improvements in the successful deployment of VCD more
generally. Within the same study period, the rates of
successful other VCD deployment declined from 98.3% to
97.7% from 2005 to 2007, indicating that the improving
clinical and deployment success in StarClose-treated pa-
tients was not reflective of overall improvement in VCD
successful deployment rates.
itutional Volumes
ice deployment without subsequent occurrence of access site complication,
erator experience with the StarClose vascular closure device (VCD).
ith Annual Institutional Volume >2,400 VCD Implants per Year
device deployment without subsequent occurrence of access site complica-
ure device (VCD). Three phases of the learning curve are noted: early rapid
cess (phase II), between 23 and 50 average implants per operator, andl Inst
ul devrtile W
essful
ar clos
al sucer operator at the institution.
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88The findings of the current analysis are consistent with
the CLIP (Clip Closure in Percutaneous Procedures) trial,
the initial randomized trial exploring the safety and efficacy
of the StarClose VCD. The CLIP trial, which included 275
patients undergoing interventional coronary procedures (in
addition to 208 in the diagnostic arm), demonstrated an
overall device success rate of 86.8% in the interventional
group and 94.1% in the diagnostic group, where device
success was defined as attainment of final hemostasis within
5 min of device deployment and freedom from major
vascular complication. These results appear to correlate very
closely with the early outcomes of our current analysis of
NCDR that demonstrated initial device success of 89.3%
for the interventional patients compared with 95.1% for the
diagnostic cases. These small differences may represent
improvements in outcomes due to device refinement (com-
paring the commercially available StarClose platform to the
initial platform studied during the CLIP trial) or potentially
due to under-reporting of adverse events in the voluntary
NCDR registry compared with the initial randomized
clinical trial. In addition, the results of this analysis confirm
the findings of earlier single-center studies of vascular
closure that explored the learning effects associated with
accumulating experience in using a specific VCD. Warren et
al. (22) identified a sharp increase in procedural success after
the first 50 deployments of the original Angio-Seal collagen
plug VCD (St. Jude Medical, St. Paul, Minnesota), whereas
Balzer et al. (5) reported significant decline in procedural
Table 4. Changes in Patient Characteristics Over Time: Large Institutions
Phase I
Early Learning %
Phase II
Expanded Use %
StarClose implants 52,389 10,884
Implant experience at
end of phase
245.1 223.2 703.8 312.4
PCI cases 15,688 29.9 3,080 28.3
Female 21,057 40.1 4,427 40.8
Age 62.3 12.5 62.3 12.6
Body mass index 30.1 6.6 30.3 6.7
Body mass index 20 kg/m2 1,432 2.7 316 2.9
History of peripheral vascular
disease
4,117 7.9 925 8.5
History of diabetes 14,234 27.2 3,068 28.2
History of renal insufﬁciency 2,358 4.5 394 3.6
History of dialysis 674 1.3 125 1.3
Emergent status 2,395 4.6 602 5.5
Urgent status 14,479 27.6 3,434 31.6
Use of bivalirudin 7,346 14.0 1,143 10.5
Use of glycoprotein IIb/IIIa
antagonist
6,418 12.3 1,319 12.1
Values are n, mean SD, or %.
NA not applicable; PCI percutaneous coronary intervention; VCD vascular closure device.failures using the Prostar suture-mediated closure device(Abbott Vascular) during peripheral interventional proce-
dures after 100 cases.
Quantification of learning curve effects associated with
medical device implant procedures is critical in developing
expectations for “real world” results of such procedures
outside of the context of pre-approval clinical trials. In
addition, quantifying the learning curve of VCD and other
implantable medical devices will allow a more informed
assessment of the need for, and duration of, training and
support as new technologies diffuse into routine clinical
practice. It is important to note that learning and improve-
ment of outcomes appears to continue even at high rates of
average operator or institutional device-specific volume,
which is consistent with learning curve theory. A better
understanding of learning curve effects will also help inform
objective evaluations of new medical device safety, as the
influence of expected human learning might be separable
from intrinsic device performance safety issues.
Study limitations. Several limitations, which limit the gen-
eralizability of the results to other medical devices or
environments, are present in this study. The CathPCI
registry did not have consistent documentation of individual
operator-unique identifier information, thereby precluding
learning curve analysis at the level of the operating physi-
cian. In addition, the registry does not collect information
about which member of the clinical team actually deployed
the device. The definition of VCD success is self-reported
in the registry; however, we have previously shown that
self-reported VCD success is closely associated with vascular
00 VCD Implants During Study)
Phase III
teady State %
Total
Experience %
p Value
Phase I vs. II
p Value
Phase II vs. III
18,281 81,554
,139 583.2 NA 0.001 0.001
4,440 24.3 23,208 28.5 0.001 0.001
7,528 40.5 33,012 40.5 0.001 0.396
62.6 12.6 62.3 12.5 0.039 0.071
30.4 6.7 30.2 6.6 0.001 0.103
455 2.5 2,203 2.7 0.001 0.079
1,580 8.6 6,622 8.1 0.015 0.984
4,957 27.1 22,259 27.3 0.007 0.002
808 4.4 3,560 4.4 0.001 0.001
199 1.1 998 1.2 0.007 0.006
934 5.1 3,931 4.8 0.001 0.112
5,404 29.6 23,317 28.6 0.001 0.001
1,923 10.5 10,412 12.8 0.001 0.625
1,818 9.9 9,555 11.7 0.001 0.001(>1,6
S
1complications rates following VCD deployment (16). Im-
pc
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89portantly, NCDR CathPCI data registry is a voluntary
clinical quality and outcomes registry in which endpoints,
such as VCD deployment failure, as well as vascular com-
plication rates, are not universally audited or adjudicated.
Conclusions
Significant learning curve effects influence the safety and
effectiveness of a recently introduced novel VCD in which
between 75 and 130 deployments of the device, per attend-
ing physician, were required to achieve the highest levels of
device deployment success and safety. The observed insti-
tutional learning curve is associated with institutional vol-
ume and teaching status and demonstrates a multiphasic
pattern indicating potential variation in patients selected to
undergo device deployment and the variable adoption of a
new technology by providers within an institution.
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ppendix
Learning curve model. To quantify the magnitude of the
learning curve effect, we modeled the learning curve as a
cumulative success function represented as the simple log-
linear equation (1):
probability of success (at nth implant)  1  k  n–b
where k is the intercept constant representing predicted
probability of failure for the first device implant, and b is the
learning curve coefficient. As b increases, the learning curve
flattens (becomes less steep) so that it takes longer to achieve
an improvement in outcomes.
